In this episode of the Scope of Things, host Deborah Borfitz covers concerns surrounding the study and treatment of obesity, a new “opening doors” initiative to clinical trials, debate over the European Union AI Act, the first international-level clinical study using secure multiparty computation, a hopeful treatment for kids with lethal brain tumors, and a ChatGPT tool created by the NIH to match potential volunteers to relevant studies. Joining the conversation is Orr Inbar, CEO and co-founder of QuantHealth, who discusses how his company is using AI to simulate clinical trials to alleviate costs and efficiency issues for the notoriously complicated drug development process. He also shares the proprietary tech powering QuantHealth’s AI and where he sees AI heading as 2025 unfolds.
SHOW NOTES
News Roundup
Perspectives on the EU AI Act
- Insights about the rollout in Clinical Research News
- Article in Clinical Research News about discussion at SCOPE Europe
Secure multiparty computation
Cell therapy for childhood brain cancer
TrialGPT tool
- Study in Nature Communications
Guest
Orr Inbar, CEO and Co-Founder of Quant Health
GUEST BIO
Orr Inbar, CEO and Co-Founder, QuantHealth
Orr Inbar, CEO and Co-Founder of QuantHealth, an AI-powered clinical trial design company that works with three of the top ten pharmaceutical companies globally. Orr’s technical background spans data science, biomedical research, software engineering, and artificial intelligence, all with a focus on healthcare. Drawing upon this experience, Orr founded QuantHealth to address the disparities in clinical research that he felt could be overcome with novel quantitative methods to increase the success rate of clinical trials.